Company: MVIS
Filing Date: 2025-03-26
Form Type: 10-K
Source: 0001641172-25-000783
Chunk: 37

Company: MICROVISION, INC.
Filing Date: 2025-03-26
Form: 10-K
Item: Item 1A
Chunk 37
---
: principal
preservation, adequate liquidity, and return. As of December 31, 2024, our cash and cash equivalents are comprised of short-term highly
rated (A rated securities and above) money market savings accounts and our short-term investments are comprised of highly rated corporate
and government debt securities (A rated securities and above). The values of cash and cash equivalents and investment securities, available-for-sale
as of December 31, 2024, are as follows (in thousands):

    Amount  
    Percent 
  
    Cash and cash equivalents 
    $54,486  
     72.9%
  
    Less than one year 
     20,216  
     27.1 

    $74,702  
     100.0%

Foreign
Exchange Rate Risk

Our
major contract and collaborative research and development agreements, product sales, and licensing activity payments are currently made
in U.S. dollars or Euros. Changes in the relative value of the U.S. dollar to the Euro and other currencies may affect revenue and other
operating results as expressed in U.S. dollars. In addition, our international subsidiary financial statements are denominated in Euros.
As such, the consolidated financial statements will continue to remain subject to the impact of foreign currency translation as our international
operations continue to expand. In the future, we may enter into foreign currency hedges to offset material exposure to currency fluctuations
when we can adequately determine the timing and amounts of the exposure.

30

ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS

    Page
  
    Report of Independent Registered Public Accounting Firm (Moss Adams LLP, Seattle, Washington, PCAOB ID:659)
     
    32

    Consolidated Balance Sheets as of December 31, 2024 and 2023
     
    34

    Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022
     
    35

    Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022
     
    36

    Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024, 2023 and 2022
     
    37

    Consolidated Statements of Cash Flows for the years ended December 31, 202